Multiple Myeloma | Specialty

The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.

Dr Baljevic on Advancements in the Management of Newly Diagnosed Multiple Myeloma

May 16th 2024

Muhamed Baljevic, MD, discusses key trial updates and advancements with quadruplet therapy in newly diagnosed multiple myeloma.

Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma

May 16th 2024

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

Dr Jagannath on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

May 14th 2024

Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Dr Ignatz-Hoover on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

May 14th 2024

James Ignatz-Hoover, MD, PhD discusses sequencing CAR T cell therapies and bispecific agents in treating pretreated patients with multiple myeloma.

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

May 13th 2024

Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.

Dr Jagannath on the Safety Considerations With CAR T-Cell Therapy Multiple Myeloma

May 10th 2024

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.

Dr Ignatz-Hoover on Bispecific Antibodies in the Multiple Myeloma Treatment Armamentarium

May 9th 2024

James Ignatz-Hoover, MD, PhD, discusses the current arsenal of FDA-approved bispecific antibodies in multiple myeloma.

Dr Jurcic on the Evolution of Combination Therapies in the Management of Myelofibrosis

May 8th 2024

Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.

Earlier CAR T Use in Multiple Myeloma: Game Changer or Boutique Medicine?

May 7th 2024

Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.

Dr Battiwalla on Advancements in the Multiple Myeloma Treatment Paradigm

May 6th 2024

Minoo Battiwalla, MD, discusses recent advancements in the multiple myeloma treatment paradigm.

AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward

May 6th 2024

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma

May 3rd 2024

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.

NXC-201 Receives Orphan Drug Designation in the European Union for Multiple Myeloma

May 3rd 2024

The CAR T-cell therapy NXC-201 has received orphan drug designation from the European Commission for patients with multiple myeloma.

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024

Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.

Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma

April 29th 2024

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

April 25th 2024

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.

Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma

April 25th 2024

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

April 24th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.